While there are many advances in Parkinson’s Disease (PD), such as identification of new biomarkers to measure disease progression, valuable insights in study design coming from Alzheimer’s Disease trials, and creative approaches for patient recruitment, challenges still remain in this therapeutic area.

PD study designs require special thought, especially for therapies that have the potential to modify the course of the disease, since clinical outcomes can be confounded by the symptomatic effect of treatment. With our years of clinical trial experience in PD, we can help you implement specific study design features.

Download our whitepaper to learn more about:

• Current clinical research trends in PD

• How establishing more sensitive and specific biomarker endpoints can decrease the cost of studies, while requiring fewer patients

• How to improve recruitment rates and motivate sites